

Hepatobiliary and Pancreas Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

LOCOREGIONAL + SYSTEMIC

NRG GI012

Atezo/bev, Durva/treme,
Nivo/ipi w/wo SBRT

Coord: B. Nguyen
Accrual: 1/5

FIRST LINE

UCI 22-106

STAT3 + Atezolizumab and Bevacizumab
(Slot request required)

Coord: H. Nguyen
Accrual: 10/15

UCI 22-211

MED1572 (IgG1 mAb) ± Bev
Suspended for additional cohort

Coord: B. Nguyen
Accrual: 3/8

UCI 23-104

Livmoniplimab + Budigalimab
Atezolizumab + Bevacizumab
Tremelimumab + Durvalumab
Suspended until Q2 2026

Coord: S. Duong
Accrual: 3/7

SECOND LINE/THIRD LINE

UCI 16-94

TATE + Nivolumab

Coord: S. Duong
Accrual: 34/48

UCI 24-09

RYZ801 (GPC3 radiotherapeutic)

Accrual: 1/10
Coord: H. Nguyen

UCI 23-215

AZD5851 (GPC3 Autologous CAR-T)
**Central testing for GPC3/GPC3
naïve**

Suspended until Q3 2026

ETCTN 10703

Sapanisertib (mTOR kinase
inhibitor) + Cabozantinib
B-catenin positivity during Phase 2

Coord: S. Duong
Accrual: 0/3

UCI 25-06

ABBV-324 (GPC3 ADC)

Coord: M. Duron
Accrual: 2/3

UCI 25-218

Visugromab (IgG4 GDF-15)
Nivolumab and Lenvatinib, or
Lenvatinib/double placebo

DOT approved



■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

SYSTEMIC + OPERATIVE	FIRST LINE	SECOND LINE+	BRAIN METASTASES
<u>ETCTN 10608</u> Gemcitabine + Cisplatin + Durva Neo/Adjuvant for <u>high-risk resectable ICC</u> Pending signatures Coord: H. Nguyen Accrual: 2/3	<u>UCI 22-211 (GEMINI)</u> <u>MED1572 (IgG1 mAb) or</u> <u>AZD2936 (TIGIT) ±</u> <u>gemcitabine and cisplatin</u> <i>Slot request</i> Coord: B. Nguyen Accrual: 4/8	<u>UCI 23-200</u> AZD0901 (CLND18 ADC) <i>Central prescreening</i> Suspended until late Q2 2026 Coord: S. Duong Accrual: 5/10	<u>NRG BN013</u> SRS vs. FSRS RT Brain RT naïve Coord: J. Balangue Accrual: 1/5
	<u>UCI 21-10</u> TJ033721 (CLDN18 Inhibitor) + Gem/Cis/Durva <i>Slot request</i> Coord: B. Nguyen Accrual: 28/35	<u>UCI 25-137</u> Nanvuranlat (LAT1 inhibitor) vs. Physician choice chemotherapy Pending budget/CTA/IRB	
	<u>UCI 25-204 (Artemide 2)</u> Rilvegostomig or Durvalumab with Gemcitabine/Cisplatin Pending IRB/CTA/Budget	<u>UCI 23-85</u> EpCAM inhibitor <i>Slot request</i> Coord: H. Nguyen Accrual: 7/18	



FIRST LINE LA/METASTATIC

SECOND LINE

UCI 23-200

AZD0901 (CLND18 ADC) with
NAL-IRI or Gemcitabine

Coord: S. Duong
Accrual: 5/10

UCI 25-216

Relacorilant w/gem/nab-pcalitaxel
mPDAC diagnosed w/in 6 weeks

DOT approved

UCI 24-105

Pitavastatin + Gemcitabine/Nab-paclitaxel
Stable disease after 2 months of treatment w/gem/nab-paclitaxel

Coord: S. Duong
Accrual: 0/18

UCI 21-10

TJXX (CLDN18 Inhibitor) +
gemcitabine + nab-paclitaxel

Slot request
Coord: B. Nguyen
Accrual: 25/35

UCI 25-229

3082-CL-0301 (KRAS G12D mPDAC)
w/mFOLFIRINOX or NALIRIFOX

DOT approved

UCI 25-228

ODM-212 (Hippo pathway)
PDAC – Gemcitabine/Nab-paclitaxel

Pending accelerated activation

UCI 22-51

ASP2138 (CLDN18.2 BiTe) with
FOLFIRINOX

Coord: S. Duong
Accrual: 32/35

UCI 26-21

3082-CL-0301 (KRAS G12D mPDAC)
w/FOLFIRINOX or gemcitabine/nab-
paclitaxel

Status: IRB/CTA/Budget

FIRST LINE SUPPORTIVE CARE

UCI 25-120

Ponsegromab (GD15 blocker) vs.
placebo for cachexia

Status: Budget/CTA/IRB

UCI 25-140

Narmafotinib w/mFOLFIRINOX
mPDAC diagnosed w/in 6 weeks

Slot request
Coord: B. Nguyen
Accrual: 0/7



BORDERLINE/ LOCALLY ADVANCED

ETCTN-10366

M3814 (Peposertib) + radiation
Coord: S. Duong
Accrual: 12/18

ETCTN-10464

Olaparib + Durvalumab + radiation

Coord: S. Duong
Accrual: 1/5

UCI 23-134

Padeliporfin Vascular targeted
photodynamic therapy
Pancreatic head/uncinate

Coord: H. Nguyen
Accrual: 5/8

NRG-GI011

Dose escalated radiation

Coord: B. Nguyen
Accrual: 0/10

RECURRENT/EXHAUSTIVE

UCI 24-08

SPEDOX -6 (Protein
encapsulated doxorubicin)
KRAS Mutation

Coord: B. Nguyen
Accrual: 7/67

UCI 24-113

BMS-986482 (Treg inducer)

PI: Dr. Chow
Coord: S. Duong
Accrual: 2/5

Review Biomarker Based Solid Tumors Pages 6 and 7

ETCTN 10522

CA4948 + gemcitabine + nab-
paclitaxel

Coord: B. Nguyen
Accrual: 4/6

BRAIN METASTASES

NRG BN013

SRS vs. FSRS RT

Brain RT naïve

Coord: M. Duron
Accrual: 1/5



SECOND LINE+

ETCTN 10479

Lu-177 + Sunitinib

Well or moderately differentiated PNET
Up to one line of systemic therapy not
including somatostatin
Slot request required

Coord: H. Nguyen
Accrual: 0/3

UCI 25-75

CRN09682 (NDC MMAE)
NET/NEC/other solid tumors with
SST2 expression on PET/CT
Slot request required

Coord: J. Balangue
Accrual: 0/15

UCI 24-138

Various Neuroendocrine including
Gastroenteropancreatic NEN with DLL3
expression on IHC
Slot request required

PI: Dr. Park
Coord: S. Duong
Accrual: 2/5

Mutation based studies allowing Pancreatic, liver, and Biliary cancers + other solid tumors

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

CLAUDIN 18.2

UCI 22-51

ASP2138 (CLDN18.2 BiTe)

Pancreatic and Gastric/GEJ

PI: Dr. Dayyani
Status: On hold

ALK

UCI 21-241

NVL- 655 (ALK inhibitor)

PI: Dr. Nagasaka
Status: Accruing

SMARCA2

UCI 25-194

Drug: PLX-61639 (SMARCA2 degrader)

Inclusive of all solid tumors with SMARCA4 mutations

PI: Dr. Villalflor
Status: IRB/CTA/Budget

HER2

ETCTN-10495

(DS8201a + Neratinib)

PI: Dr. Dayyani
Status: Suspended

MTAP

UCI 24-197

TNG456 (PRMT5 inhibitor)

MTAP NGS/IHC local testing

PI: Dr. Park
Status: Accruing

KRAS

UCI 25-163

Drug:BBO-11818

Inclusive of all solid tumors with KRAS G12C, G12D, G12V
Emphasis on NSCLC, CRC, and PDAC

PI: Dr. Arter
Status: IRB/CTA/Budget

Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: B. Nguyen

Status: Suspended for analysis

UCI 24-142

VET3-TGI (IL-12 and TGF-B inhibiting vaccine) ± Pembrolizumab
Intra-tumoral or IV

PI: Dr. Uchio

Status: Accruing with slot request

UCI 25-16

ODM-212 (Hippo pathway)

Reach out to coordinator for selected tumor types

PI: Dr. Dayyani

Status: Accruing with slot request

UCI 25-228

ODM-212 (Hippo pathway)

Lung - Sotorasib
Mesothelioma – Ipilimumab/Nivolumab
PDAC – Gemcitabine/Nab-paclitaxel

Pending accelerated activation

ETCTN 10579

Drug: ZEN-3694 (BET Inhibitor) + capecitabine
Inclusive of all solid tumors in dose escalation

PI: Dr. Lee

Status: Accruing with slot request

BLOOD COLLECTION

UCI 21-124

ctDNA collection during HBP
workup

Coord: J. Balangué
Accrual: 16/20

UCI 23-10/PRECEDE

(Blood collection for early
detection of pancreatic
cancer)

Coord: J. Balangué
Accrual: 1/20

UCI 22-55

Blood and biomarker
collection for early detection
and diagnosis of DNA
Deficient Hereditary Cancers

Investigators: Dr. Jennifer
Valerin and Dr. Nicholas
Pannunzio

BEHAVIORAL

UCI 25-177

Refinement and usability of e-
support for pancreatic cancer
patients

Investigator: Dr. Jacqueline Kim